Shionogi: US Hospital Burden of Carbapenem-Resistant Acinetobacter baumannii (CRAB)

This retrospective cohort study undertaken by Shionogi, Inc., Florham Park, NJ, analyzed data from the PINC AI™ Database between January 1, 2018, and December 31, 2022, to describe the incidence of Acinetobacter baumannii and carbapenem-resistant A. baumannii (CRAB) across US hospitals. The study found that A. baumannii was identified in approximately 1% of adult hospitalizations. More concerningly, over a third of these encounters involved CRAB, and the incidence of CRAB steadily increased during the study period, with significant regional variations. Patients with CRAB exhibited higher in-hospital mortality and longer hospital stays. They were more likely to have co-infections with other Gram-negative pathogens than those with carbapenem-susceptible A. baumannii. The findings underscore the growing clinical burden of CRAB in US hospitals and highlight the urgent need for new treatment options and robust infection control strategies, including Shionogi’s cephalosporin antibiotic, FETROJA (cefiderocol).

Lodise TP, Nguyen ST, Margiotta C, Cai B. Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018 and 2022. BMC Infect Dis. 2025 Apr 17;25(1):549. doi: 10.1186/s12879-025-10749-1. PMID: 40247165.

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-025-10749-1